Trimetrexate
Trials 13 · a red edge is where a trial was stopped
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trimetrexate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00119301 ↗ |
| Known as | TMTX | “To study the safety and effectiveness of trimetrexate (TMTX) plus leucovorin calcium rescue (LCV) in the treatment of Pneumocystis carinii pneumonia (PCP) in patients who have...” NCT00000724 ↗7“To evaluate the safety and effectiveness of trimetrexate (TMTX) given at increasing doses along with the leucovorin calcium (LCV) for treating Pneumocystis carinii pneumonia...” NCT00000998 ↗ “Trimetrexate (TMTX) was chosen for this trial because it was found to be much more potent than sulfamethoxazole/trimethoprim (SMX/TMP) against the PCP organism in laboratory tests.” NCT00001013 ↗ “This study compares therapy with trimetrexate (TMTX) and leucovorin (LCV) to standard therapy and standard therapy plus high-dose steroids (methylprednisolone).” NCT00000730 ↗ “oral trimetrexate glucuronate (TMTX) and leucovorin calcium every 12 hours for 21 days (weeks 0-2)” NCT00003776 ↗ “investigational drug therapy (trimetrexate plus leucovorin calcium (TMTX / LCV))” NCT00000714 ↗ “investigational drug trimetrexate (TMTX) with leucovorin rescue (LCV)” NCT00001016 ↗ “trimetrexate glucuronate (TMTX)” NCT00002120 ↗ |
| Known as | trimetrexate glucuronate | “oral trimetrexate glucuronate (TMTX) and leucovorin calcium every 12 hours for 21 days (weeks 0-2)” NCT00003776 ↗ |
| Route | Intravenous | “Both drugs are given by intravenous infusion” NCT00000714 ↗ |